This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Cortical oxygen supply during postural hypotension is further decreased in Alzheimer’s disease, but unrelated to cholinesterase-inhibitor use

Authors

van Beek, Arenda H. E. A., Sijbesma, Jaap C., Jansen, Rene W. M. M., Rikkert, Marcel G. M. Olde, Claassen, Jurgen A. H. R.

Journal

Journal Of Alzheimer's Disease: JAD, Volume: 21, No.: 2, Pages.: 519-526

Year of Publication

2010

Abstract

Cerebrovascular function and structure of the cortical cerebral microvessels are profoundly altered in patients with Alzheimer’s disease (AD). The functional hemodynamic consequences of such changes, however, remain essentially unknown. Cholinesterase inhibitors (ChEIs) potentially affect brain perfusion through either augmentation or inhibition of cerebral vasodilatation. This study investigated the cerebrovascular regulation during postural changes in AD before and after treatment with the ChEI galantamine. In 21 AD patients and 20 controls, blood pressure (BP–Finapres), frontal cortical oxygenation (near-infrared-spectroscopy), and cerebral blood flow velocity in the middle cerebral artery (transcranial Doppler ultrasonography) were measured following a hypotensive challenge induced by postural change. In AD, measurements were repeated after 10 (SD 4) weeks of galantamine. Baseline cerebrovascular resistance was higher in AD (AD 2.83 (0.87) mmHg/cm/s, control 2.24 (1.3) mmHg/cm/s, p=0.010). 13 AD patients and 17 controls had a sufficiently large postural drop in BP (> 10 mmHg). AD patients had a larger postural decline in the frontal cortical concentration of total hemoglobin (Delta [tHb] AD=1.03 (0.70) micromol/l, control =0.30 (0.90) micromol/l, p=0.015). Moreover, the reduction in oxygenated hemoglobin was 57% larger in AD (p=0.085). Unexpectedly, the postural changes in BP were smaller in AD. Galantamine treatment affected neither orthostatic BP nor the decrease in [tHb]. In conclusion, even for moderate orthostatic hypotension during commonly occurring postural changes, cerebral cortical tissue perfusion declined more in AD, suggesting increased ischemic vulnerability of the brain. Galantamine neither improved nor impaired cerebrovascular regulation.;

Keywords

administration & dosage, aged, alzheimer disease, blood, cerebrovascular, cerebrovascular circulation, cholinesterase inhibitors, drug effects, drug therapy, female, galantamine, humans, hypotension orthostatic, male, metabolism, microcirculation, middle cerebral artery, oxygen, oxyhemoglobins, physiology, physiopathology, regulation, spectroscopy nearinfrared, ultrasonography, ultrasonography doppler transcranial

Countries of Study

Netherlands

Types of Dementia

Alzheimer’s Disease

Types of Study

Non randomised controlled trial

Type of Outcomes

Physical Health

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime